Episode 8. Management of Newly Diagnosed CLL
Blood Cancer Talks
00:00
The Benefits of Recruitment Plus Microplaques for CLF
There is no retuximaborobinitism map. So it's just able to give us all oral treatments. And I think data from our study from MD Anderson, the Capri-Wit study, and there are some other studies as well of these double-edged trip that's ongoing. We'll have to see how their long-term data looks,. because the patients who start asking, right, should I use a group with microplaques or patients and the doctors, or should I just do a microplaques with a V2-sumA?
Transcript
Play full episode
